| scholarly article | Q13442814 |
| P2093 | author name string | Nava Zisapel | |
| Moshe Laudon | |||
| Alan G Wade | |||
| Tali Nir | |||
| Naama Fund | |||
| Gil Harari | |||
| Anat Frydman-Marom | |||
| Mildred Farmer | |||
| P2860 | cites work | Alzheimer's Disease | Q22248111 |
| Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes | Q22299199 | ||
| Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia | Q22306021 | ||
| “Mini-mental state” | Q25938989 | ||
| The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research | Q29547257 | ||
| Sleep drives metabolite clearance from the adult brain | Q29620065 | ||
| A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. | Q30405370 | ||
| Self-reported sleep and β-amyloid deposition in community-dwelling older adults | Q30571257 | ||
| A five-point change in Modified Mini-Mental State Examination was clinically meaningful in community-dwelling elderly people. | Q51890965 | ||
| Actigraphy in agitated patients with dementia. Monitoring treatment outcomes. | Q53287403 | ||
| Assessment of older people: self-maintaining and instrumental activities of daily living | Q66829682 | ||
| Prolonged-release melatonin for the treatment of insomnia in patients over 55 years | Q94706775 | ||
| Poor sleep quality impairs cognitive performance in older adults | Q45767463 | ||
| The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. | Q45936313 | ||
| Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem. | Q45954747 | ||
| The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease. | Q45957440 | ||
| Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers | Q46397136 | ||
| Late evening brain activation patterns and their relation to the internal biological time, melatonin, and homeostatic sleep debt | Q46839791 | ||
| Melatonin and the human hippocampus, a time dependent interplay | Q48113837 | ||
| Sleep evaluation by actigraphy for patients with Alzheimer disease | Q48161072 | ||
| Effects of prolonged-release melatonin and zolpidem on postural stability in older adults | Q48257449 | ||
| Prolonged-release melatonin for children with neurodevelopmental disorders | Q48294909 | ||
| Monozygotic twins with Alzheimer's disease treated with melatonin: Case report | Q48308042 | ||
| Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response | Q48330904 | ||
| Low sleep efficiency in patients with cognitive impairment. | Q48391757 | ||
| Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease | Q48687277 | ||
| Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking | Q48770281 | ||
| Melatonin plus physical exercise are highly neuroprotective in the 3xTg-AD mouse | Q48771399 | ||
| Improvement of sleep quality in elderly people by controlled-release melatonin | Q48807807 | ||
| The association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims data | Q33472009 | ||
| Do sleep complaints contribute to age-related cognitive decline? | Q33746159 | ||
| Clinical trials of controlled-release melatonin in children with sleep-wake cycle disorders | Q33914514 | ||
| The role of sleep in learning and memory | Q34100278 | ||
| Measuring well-being rather than the absence of distress symptoms: a comparison of the SF-36 Mental Health subscale and the WHO-Five Well-Being Scale. | Q34209492 | ||
| The Sleep Disorders Inventory: an instrument for studies of sleep disturbance in persons with Alzheimer's disease | Q34278439 | ||
| Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value | Q34416921 | ||
| Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. | Q34433710 | ||
| Impaired declarative memory consolidation during sleep in patients with primary insomnia: Influence of sleep architecture and nocturnal cortisol release. | Q34552261 | ||
| Benzodiazepine use and risk of dementia: prospective population based study | Q34643603 | ||
| A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group | Q34744744 | ||
| Memory disorders associated with consumption of drugs: updating through a case/noncase study in the French PharmacoVigilance Database | Q35629744 | ||
| Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial | Q36372805 | ||
| Therapeutic application of melatonin in mild cognitive impairment. | Q36576496 | ||
| Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis | Q36897422 | ||
| Sleep quality and preclinical Alzheimer disease | Q36913338 | ||
| Synthesis and comparison of the meta-analyses evaluating the efficacy of memantine in moderate to severe stages of Alzheimer's disease | Q37004843 | ||
| Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease | Q37070699 | ||
| Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease | Q37097780 | ||
| The impact of analytic method on interpretation of outcomes in longitudinal clinical trials | Q37134325 | ||
| Clinical trial design issues in mild to moderate Alzheimer disease | Q37341400 | ||
| Modification of the relationship of the apolipoprotein E ε4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep | Q37384609 | ||
| Sleep and Alzheimer disease pathology--a bidirectional relationship | Q37691522 | ||
| Is modulation of nicotinic acetylcholine receptors by melatonin relevant for therapy with cholinergic drugs? | Q37732559 | ||
| Effects of the use of hypnotics on cognition | Q37870513 | ||
| Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial | Q38389742 | ||
| Effects of a diet integration with an oily emulsion of DHA-phospholipids containing melatonin and tryptophan in elderly patients suffering from mild cognitive impairment. | Q38476020 | ||
| What is the clinically relevant change on the ADAS-Cog? | Q38482318 | ||
| The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia | Q39605807 | ||
| Neuroprotective effects of melatonin | Q41200848 | ||
| Sleep Problems and Institutionalization of the Elderly | Q42154850 | ||
| Determining the minimum clinically important differences for outcomes in the DOMINO trial. | Q42675662 | ||
| The effect of self-reported habitual sleep quality and sleep length on autobiographical memory. | Q43619059 | ||
| Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia | Q44236057 | ||
| Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia | Q44240659 | ||
| Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia | Q44556211 | ||
| Sleep evaluation by actigraphy for patients with Alzheimer disease--reply | Q45338351 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| multicenter clinical trial | Q6934595 | ||
| melatonin | Q180912 | ||
| placebo | Q269829 | ||
| P304 | page(s) | 947-961 | |
| P577 | publication date | 2014-06-18 | |
| P1433 | published in | Clinical Interventions in Aging | Q5133768 |
| P1476 | title | Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial | |
| P478 | volume | 9 |
| Q91738117 | Association between circadian rhythms and neurodegenerative diseases |
| Q38969302 | Association of urinary melatonin levels and aging-related outcomes in older men. |
| Q37089820 | Associations between Sleep, Cortisol Regulation, and Diet: Possible Implications for the Risk of Alzheimer Disease. |
| Q39190597 | Circadian Disruption Associated with Alzheimer's Disease |
| Q64882308 | Circadian Rhythm and Alzheimer's Disease. |
| Q26772851 | Clinical management of sleep disturbances in Alzheimer's disease: current and emerging strategies |
| Q26775386 | Cognitive remission: a novel objective for the treatment of major depression? |
| Q30400537 | Evaluation of the efficacy of randomized controlled trials of sensory stimulation interventions for sleeping disturbances in patients with dementia: a systematic review. |
| Q35740613 | Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials |
| Q40900071 | Is suvorexant a better choice than alternative hypnotics? |
| Q98386892 | Low-dose melatonin for sleep disturbances in early-stage cirrhosis: A randomized, placebo-controlled, cross-over trial |
| Q39178920 | Mechanisms of Melatonin in Alleviating Alzheimer's Disease |
| Q38834700 | Melatonin for Sleep Disorders in Patients with Neurodegenerative Diseases. |
| Q92404286 | Melatonin: Clinical Perspectives in Neurodegeneration |
| Q28075345 | Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms |
| Q64880531 | Natural Compounds for Alzheimer's Disease Therapy: A Systematic Review of Preclinical and Clinical Studies. |
| Q47557441 | New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation |
| Q92157647 | Pharmacologic Management of Agitation in Patients with Dementia |
| Q30422188 | Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations |
| Q39010202 | Pharmacotherapies for sleep disturbances in dementia. |
| Q49555902 | Pineal Calcification, Melatonin Production, Aging, Associated Health Consequences and Rejuvenation of the Pineal Gland. |
| Q34461143 | Reversal of cognitive decline: a novel therapeutic program |
| Q61804015 | Role of immune-pineal axis in neurodegenerative diseases, unraveling novel hybrid dark hormone therapies |
| Q38610500 | Sleep, Cognition and Dementia |
| Q48125798 | Subthreshold Concentrations of Melatonin and Galantamine Improves Pathological AD-Hallmarks in Hippocampal Organotypic Cultures |
| Q26777958 | The Role of Sleep and Sleep Disorders in the Development, Diagnosis, and Management of Neurocognitive Disorders |
| Q38675828 | The Safety of Melatonin in Humans |
| Q91655147 | The effect of anti-dementia drugs on Alzheimer disease-induced cognitive impairment: A network meta-analysis |
| Q34358480 | Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders |
| Q100523509 | Therapeutic implications of hypothalamic-pituitary-adrenal-axis modulation in Alzheimer's disease: A narrative review of pharmacological and lifestyle interventions |
| Q89563603 | Therapy for Insomnia and Circadian Rhythm Disorder in Alzheimer Disease |
| Q38913876 | Treatment of Sleep Disorders in Dementia |
| Q38868297 | Update on melatonin receptors: IUPHAR Review 20. |
| Q35014204 | Wake-active neurons across aging and neurodegeneration: a potential role for sleep disturbances in promoting disease |
Search more.